Ionis Pharmaceuticals, headquartered in Carlsbad, California, develops drugs using antisense technology and has five marketed medicines, including SPINRAZA and QALSODY, with a pipeline focused on neurology and cardiology. The company employs 927 people and has nine medicines in Phase III development.
Ionis Pharmaceuticals (IONS) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Ionis Pharmaceuticals's actual EPS was -$0.66, beating the estimate of -$1.15 per share, resulting in a 42.39% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
